🟢 Definium Therapeutics is trading 10% up in pre-market after a steep prior-session decline

Definium Therapeutics is trading 10.34% higher at $33.50 in pre-market after a steep decline in the prior session.

• The Nasdaq is up 1.50% pre-market, consistent with a broader rebound in risk-sensitive shares.
• No new company-specific announcement was identified for November 6.
• The latest news was the November 4 announcement of Phase 3 presentations at the NEI Fall Congress. The event is ongoing, but available evidence does not establish it as the direct cause of the move.